Home Alzheimer’s Disease Phase III UNITY-CLL Trial Shows Promise for Umbralisib, Ublituximab Combo in CLL

Phase III UNITY-CLL Trial Shows Promise for Umbralisib, Ublituximab Combo in CLL

Positive topline results from the global phase III UNITY-CLL trial evaluating the combination of umbralisib plus ublituximab (U2) compared to obinutuzumab (Gazyva) plus chlorambucil (Leukeran) in patients with previously untreated and relapsed or refractory chronic lymphocytic leukemia (CLL) were announced by TG Therapeutics, the developer of the combination. 

The trial met its primary endpoint at a prespecified interim analysis, demonstrating a statistically significant improvement in progression-free survival (PFS; P< 0.0001), and will be stopped early for superior efficacy. Notably, PFS was assessed by an Independent Review Committee (IRC), and benefit was also observed across both previously untreated and relapsed or refractory patient populations.

An independent data safety monitoring board (DSMB) conducted the interim analysis and made the recommendation to stop the trial…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Cause of Alzheimer’s disease traced to mutation in common enzyme

submitted by /u/scotsman81 Continue Reading to the Source

Reflections on Living With an Incurable Illness : braincancer

(I’ve checked with the moderators to make sure this is appropriate and a good fit for this subreddit. I'm a very private person, and...

This Foramen Magnum Meningioma almost killed me 18 years ago.

submitted by /u/dkrem Continue Reading to the Source

Patients, Family & Friends, and Healthcare professionals : braincancer

I am currently a PhD student based at the Marie Curie Palliative Care Research Centre at Cardiff University. My PhD is focussed on developing...

Recent Comments